Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06057402
Title Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15)
Acronym MagnetisMM15
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Pfizer
Age Groups: adult | senior
Covered Countries USA | FRA | CAN | AUS

No variant requirements are available.